BioMarin Pharmaceuticals Inc (BMRN): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

BioMarin Pharmaceuticals ( BMRN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.1%. By the end of trading, BioMarin Pharmaceuticals rose $1.42 (2.8%) to $52.98 on average volume. Throughout the day, 1.3 million shares of BioMarin Pharmaceuticals exchanged hands as compared to its average daily volume of 1.6 million shares. The stock ranged in a price between $51.26-$53 after having opened the day at $51.26 as compared to the previous trading day's close of $51.56. Other companies within the Drugs industry that increased today were: Sangamo BioSciences ( SGMO), up 17.5%, Halozyme Therapeutics ( HALO), up 15.7%, ACADIA Pharmaceuticals ( ACAD), up 12%, and Herbalife ( HLF), up 10.1%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. BioMarin Pharmaceuticals has a market cap of $6.41 billion and is part of the health care sector. Shares are up 5.3% year to date as of the close of trading on Friday. Currently there are 11 analysts that rate BioMarin Pharmaceuticals a buy, no analysts rate it a sell, and five rate it a hold.

TheStreet Ratings rates BioMarin Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and feeble growth in the company's earnings per share.

On the negative front, Telik ( TELK), down 24.5%, Oxygen Biotherapeutics ( OXBT), down 12%, Flamel Technologies ( FLML), down 11.8%, and ImmuCell Corporation ( ICCC), down 11.6%, were all laggards within the drugs industry with Pharmacyclics Incorporated ( PCYC) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

HOLIDAY SPECIAL: Let Jim Cramer show you every trade he is making in his $2.5 Million portfolio. Join now for 14-days FREE. Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

5 Top Stocks With 100% Buy Ratings Right Now

5 Top Stocks With 100% Buy Ratings Right Now

Why I Stay Very Focused on My Individual Stocks

Why I Stay Very Focused on My Individual Stocks

7 Winners and Losers From Biggest Biotech Conference of 2017

7 Winners and Losers From Biggest Biotech Conference of 2017

Bluebird Bio Becoming Household Name With This Promising Cancer Treatment

Bluebird Bio Becoming Household Name With This Promising Cancer Treatment